Supernus price target raised to $14 from $12 at Stifel After Supernus stated that it believes it is on track to reach cash flow break-even, Stifel thinks the launches of the company's Oxtellar and Trokendi drugs are going well. Stifel believes that uptake of the company's Trokendi XR drug could improve, and it keeps a Buy rating on the stock.
Supernus raises FY14 revenue view to $115M-$118M from $105M FY14 consensus $104.44M. The company is reducing its cash burn guidance for the year from $5M-10M to approximately $5M, and raising its guidance for year end cash and marketable securities to approximately $85M. The company anticipates achieving cash flow break even by year end and being profitable in 2015.